Clinical and Translational Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2025-01-13 2122015030 来自陕西省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学
经验分享：Issue Online: 10 January 2025
Version of Record online: 10 January 2025（接收后约20天online）
Manuscript accepted: 22 December 2024
Manuscript revised: 09 December 2024
Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见)
Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答)
Need Revision: 07 October 2024(一审1个月)
Manuscript received: 05 September 2024

整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下
APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！

3 0

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-12-18 1811fd99f7m 来自佛罗里达

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：乳腺癌
经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。

31 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-09-26 ms3000001344629820 来自陕西省

投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑

33 21

展开21条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-12-20 1250080bm96暂无昵称来自北京

偏重的研究方向：肿瘤
经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10

11 0

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-10-29 ms9000000165099070

偏重的研究方向：骨科
经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。#期刊论坛##clinical and translational medicine#

55 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2023-11-16 ms2000002007484521 来自北京

查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。

92 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-11-22 ms1000001045504261 来自重庆

审稿速度:1.0 | 投稿命中率:50.0
经验分享：多久会被拒稿啊

32 0

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-04-14 ms4000000418941187 来自广东省

偏重的研究方向：肿瘤基础研究;肿瘤
经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭

0 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-11-18 ms1000002002806295 来自浙江省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：结石;细胞死亡
经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考

27 0

[GetPortalCommentsPageByObjectIdResponse(id=2247883, encodeId=b60a224e883d8, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：免疫治疗;非小细胞肺癌;微生物组学 经验分享：Issue Online: 10 January 2025 Version of Record online: 10 January 2025（接收后约20天online） Manuscript accepted: 22 December 2024 Manuscript revised: 09 December 2024 Need Revision: 02 December 2024(二审2个月，增加1位审稿人，8条审稿意见) Under Review: 08 October 2024(一个审稿人，14条审稿意见，相对容易回答) Need Revision: 07 October 2024(一审1个月) Manuscript received: 05 September 2024 整体审稿速度适中，审稿意见相对柔和，较容易回答，一审速度快前提是未找到足够多的审稿人的情况下 APC约2.7wRMB（当日汇率计算），接收后在线proof，约20天online。希望对大家有用。加油！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f8c1744425, createdName=2122015030, createdTime=Mon Jan 13 14:35:58 CST 2025, time=2025-01-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243237, encodeId=771e224323e46, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：乳腺癌 经验分享：刚中一篇，一审大概1个多月，给了大修，花了一个多月返修回去，二审大概20天左右，给了小修，然后2天返修回去后正式接收！总共四个审稿人，审稿意见还是非常中肯，其中一个审稿人提了20多个意见，回复函整整写了20页，非常的不容易，总算结果还比较好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1d432135091, createdName=1811fd99f7m, createdTime=Wed Dec 18 10:25:40 CST 2024, time=2024-12-18, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2227813, encodeId=c63f222e813de, content=投稿两天，投稿submission status 是under review，但是右边有几行小字写的是This submission is under consideration and cannot be edited. Further information will be emailed to you by the journal editorial office.，求问这是送审了还是还没分配编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4d905570358, createdName=ms3000001344629820, createdTime=Thu Sep 26 15:11:46 CST 2024, time=2024-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2243716, encodeId=15f82243e1608, content=偏重的研究方向：肿瘤 经验分享：杂志一般，类似international journal of surgery，及时if8，希望后续能维持10, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=83912531155, createdName=1250080bm96暂无昵称, createdTime=Fri Dec 20 10:51:30 CST 2024, time=2024-12-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2233938, encodeId=20572233938c9, content=偏重的研究方向：骨科 经验分享：大伙儿们，这个杂志是提交后状态就是under review吗？已经一个月了，期间也没收到送审的邮件，状态一直是under review, 很焦虑。<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>#clinical and translational medicine#, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c43b9111664, createdName=ms9000000165099070, createdTime=Tue Oct 29 15:31:03 CST 2024, time=2024-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2168782, encodeId=3e792168e820e, content=查重报告必须自己做吗？不超过5％的查重率，说实在的太难达到。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85a68567048, createdName=ms2000002007484521, createdTime=Thu Nov 16 10:29:16 CST 2023, time=2023-11-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2238482, encodeId=73682238482e9, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：多久会被拒稿啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7668181802, createdName=ms1000001045504261, createdTime=Fri Nov 22 16:09:56 CST 2024, time=2024-11-22, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2198346, encodeId=6583219834660, content=偏重的研究方向：肿瘤基础研究;肿瘤 经验分享：求教各位大佬，投稿8天，pending decision 6天还没消息，这是要直接拒吗？还是有可能送审呀？没投过pending这个状态持续这么久的😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce85486753, createdName=ms4000000418941187, createdTime=Sun Apr 14 00:22:24 CST 2024, time=2024-04-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2237657, encodeId=7250223e657d1, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：结石;细胞死亡 经验分享：杂志投稿第二天submission status 是under review （第一天晚上通稿的，投稿状态未通过）。大概12天之后回来了意见，rejected by Editorial Office。没到外审阶段，给大家一个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=447d6574313, createdName=ms1000002002806295, createdTime=Mon Nov 18 21:44:39 CST 2024, time=2024-11-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2237478, encodeId=e638223e478c0, content=转letter, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73779430130, createdName=ms9000001856552545, createdTime=Sun Nov 17 21:15:57 CST 2024, time=2024-11-17, status=1, ipAttribution=广东省)]

2024-11-17 ms9000001856552545 来自广东省

转letter

27 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务